Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 SC maintenance therapy in Crohn's disease (Japan)
jRCT2031230707Phase 3Active, not recruiting
- Sponsor
- Celltrion Healthcare
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infliximab-dyyb in Crohn's disease, sponsored by Celltrion Healthcare. Primary endpoint: Incidence rate of grade 3 or higher TEAEs. Started Apr 2024; status: active, not recruiting.
02
Drugs
infliximab-dyyb
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031230707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230707.